Tag Directory / BIOTECH     showing 81–94 of 94


Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial / American Association for Cancer Research

Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Brian Lawenda: Visual Decision Aid To Simplify Breast Cancer Treatment Choices for Women 65+

3 months / oncodaily

Runcie Chidebe: Fatima Cardoso Presents the Advanced Breast Cancer Global Decade Report 2015–2025

3 months / oncodaily

Adrian Lee: Global Research Focus on Lobular Breast Cancer at SABCS 2025

3 months / oncodaily

SABCS 2025: Tissue-Free ctDNA Surveillance Anticipates Relapse in High-Risk Early TNBC

3 months / oncodaily

Clinical characteristics and prognostic impact of HER2 low expression in breast cancer subtypes from a Brazilian real-world cohort

3 months / nature

Aydah AlAwadhi: Survivorship in Young Women with Breast Cancer is Complex

3 months / oncodaily

20 Posts Not to Miss from SABCS 2025, Part 2

3 months / oncodaily

Sibylle Loibl: Thrilled to be Back in San Antonio for SABCS 2025

3 months / oncodaily

Aleix Prat: New HER2DX Data at SABCS 2025

3 months / oncodaily

Matthew Oberley: Caris Life Sciences Unveils AI Driven Breast Cancer Recurrence Risk Project at SABCS 25

3 months / oncodaily

Paolo Tarantino: Not All Residual Disease Is Equal in TNBC

3 months / oncodaily

Harold J. Burstein: SGBCC Consensus Guideline for Early Breast Cancer

3 months / oncodaily

Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer

3 months / medicalxpress

Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial

3 months / aacr / Kathleen Medora

A historic step towards a smokefree Wales

3 months / cancerresearchuk / Cancer Research UK

Wednesday, December 10, 2025, 11:22 am / permalink 16789 / 15 stories in 3 months


Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder / MedCity

Frank Vinluan / medcitynews - Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed t…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Protego gets $130M for AL amyloidosis drug from leaders behind Vyndaqel

3 months / endpoints / Kyle LaHucik

Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder

3 months / medcitynews / Frank Vinluan

Saturday, December 6, 2025, 10:21 am / permalink 16661 / 2 stories in 3 months


A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes / Fierce

fiercehealthcare - Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from 12 former commissioners of the agency.

#healthcare #publichealth #governmentpolicy #biotech #drugdevelopment #fda #vaccinesafety

Inside the FDA’s Vaccine Uproar

2 months / kffhealthnews / Céline Gounder

CDC's ACIP pushes back planned vote on newborn hepatitis B vaccines as confusion, debate abound

3 months / fiercehealthcare

ACIP delays vote on hepatitis B birth dose to Friday

3 months / endpoints / Max Bayer

Kennedy's vaccine advisory committee delays vote on hepatitis B shots for newborns

3 months / medicalxpress

Prasad's claim of 10 Covid vaccine deaths may be an overcount: FDA sources

3 months / endpoints / Zachary Brennan

CDC panel may change longtime rule on hepatitis B shots for newborns

3 months / medicalxpress

A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes

3 months / fiercehealthcare

12 former FDA chiefs warn against vaccine policy shift

3 months / beckershospitalreview / Ella Jeffries

Former F.D.A. Commissioners Sound Alarm on Plan to Change Vaccine Policy

3 months / nytimes / Rylee Kirk

Former F.D.A. Commissioners Sound Alarm on Plan to Change Vaccine Policy

3 months / nytimes / Rylee Kirk

Thursday, December 4, 2025, 10:23 am / permalink 16565 / 10 stories in 3 months


FDA approves all ages gene therapy for spinal condition / Beckers

Ella Jeffries / beckershospitalreview - The FDA approved Novartis’ Itvisma (onasemnogene abeparvovec-brve), the company’s first and only gene replacement therapy for spinal muscular atrophy in children 2 and older, as well as for teens and adults. The therapy is designed to address the genetic …

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

FDA approves all ages gene therapy for spinal condition

3 months / beckershospitalreview / Ella Jeffries

FDA approves Novartis’ Itvisma for older patients with spinal muscular atrophy

3 months / endpoints / Ayisha Sharma

Monday, December 1, 2025, 4:21 am / permalink 16428 / 2 stories in 3 months


Novo submits high-dose Wegovy for FDA approval using voucher / Endpoints

Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment #fda

Novo Nordisk seeks FDA approval of higher-dose Wegovy

3 months / beckershospitalreview / Paige Twenter

Novo submits high-dose Wegovy for FDA approval using voucher

3 months / endpoints / Max Bayer

Saturday, November 29, 2025, 5:21 pm / permalink 16400 / 2 stories in 3 months


Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment

CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks

3 months / endpoints / Nicole DeFeudis

Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds

3 months / nytimes / Roni Caryn Rabin

Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

3 months / beckershospitalreview / Ella Jeffries

Pill form of semaglutide fails to slow Alzheimer's in large trial

3 months / medicalxpress

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

3 months / nytimes / Gina Kolata

Tuesday, November 25, 2025, 10:21 am / permalink 16294 / 5 stories in 3 months


New nasal nanodrops wipe out brain tumors in mice / Science Daily Cancer

sciencedaily - A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune pathway using gold-core spherical nucleic acids, researchers were able to reach the brain without invasive surgery. When paired with dru…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Fatma Nihan Akkoc Mustafayev: Honored to Give an Oral Presentation on Hispanic GBM Outcomes at SNO2025

3 months / oncodaily

New nasal nanodrops wipe out brain tumors in mice

3 months / sciencedaily

Nasal nanomedicine delivers immune-boosting therapy to fight brain tumors

3 months / medicalxpress

Saturday, November 22, 2025, 1:21 pm / permalink 16217 / 3 stories in 3 months


FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation / ESMO

esmo - Evidence for efficacy is based on the results from the KO-MEN-001 study

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation

3 months / esmo

FDA Approves Ziftomenib (Komzifti) for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

3 months / oncodaily

Saturday, November 22, 2025, 9:22 am / permalink 16210 / 2 stories in 3 months


Novo Nordisk rolls out lower prices for Ozempic and Wegovy / Medical Express

medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #publichealth #biotech

When Drug Price Transparency Isn’t Enough

3 months / thehealthcareblog / matthew holt

Q&A: Navigating weight loss—when to consider bariatric surgery after GLP-1 therapy

3 months / medicalxpress

Daily pill could offer alternative to weight-loss injections

3 months / newscientist

Novo Nordisk rolls out lower prices for Ozempic and Wegovy

3 months / medicalxpress

Novo Nordisk lowers self-pay prices for weight loss drugs ahead of Lilly, TrumpRx

3 months / endpoints / Zachary Brennan

Ozempic, Wegovy to be sold at $199 a month for new patients

3 months / beckershospitalreview / Paige Twenter

Thursday, November 20, 2025, 1:22 am / permalink 16131 / 6 stories in 3 months


Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns / Endpoints

Alex Hoffman / endpoints - → In what appears to be another blow to Novo Nordisk, ex-Pfizer CSO Mikael Dolsten has withdrawn his nomination to join the company's board of directors due to ...

#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Merck Makes Big Antiviral Move With $9B Deal to Land Cidara’s Late-Stage Drug for Flu Prevention

4 months / medcitynews / Frank Vinluan

Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns

4 months / endpoints / Alex Hoffman

Saturday, November 15, 2025, 3:21 pm / permalink 16003 / 2 stories in 4 months


FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths / ABC News

go - The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

US narrows use of muscle-wasting therapy after teen deaths

4 months / medicalxpress

FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing study

4 months / endpoints / Lei Lei Wu

FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths

4 months / go

Saturday, November 15, 2025, 5:21 am / permalink 15991 / 3 stories in 4 months


Bacteria Inside Brain Tumors May Affect Tumor Behavior / OncoDaily

oncodaily - Traces of bacteria inside brain tumors may affect tumor behavior Researchers found bacterial genetic and cellular elements inside brain tumor cells that appear biologically active and may influence tumor progression […]

#healthcare #publichealth #biotech #drugdevelopment

Traces of bacteria inside brain tumors may affect tumor behavior

4 months / medicalxpress

Bacteria Inside Brain Tumors May Affect Tumor Behavior

4 months / oncodaily

Saturday, November 15, 2025, 2:20 am / permalink 15988 / 2 stories in 4 months


Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera / MedCity

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer prevails in $10B bidding war for Metsera

4 months / beckershospitalreview / Ella Jeffries

Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firm

4 months / endpoints / Kyle LaHucik

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

4 months / medcitynews / Frank Vinluan

Novo Nordisk, Pfizer make personnel waves as they squabble over Metsera

4 months / endpoints / Alex Hoffman

Monday, November 10, 2025, 12:21 am / permalink 15823 / 4 stories in 4 months


Pfizer poised to buy Metsera in $10 bn deal after bidding war / Medical Express

medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer poised to buy Metsera in $10 bn deal after bidding war

4 months / medicalxpress

Novo Nordisk raises Metsera bid again, hoping to top Pfizer's latest offer

4 months / endpoints / Drew Armstrong

Saturday, November 8, 2025, 3:21 pm / permalink 15805 / 2 stories in 4 months


Back to Top


BIOTECH Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.